Horizontal Approaches to Food Standards of Identity Modernization; Public Meeting; Request for Comments, 45497-45500 [2019-18713]
Download as PDF
khammond on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 84, No. 168 / Thursday, August 29, 2019 / Notices
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–D–3092 for ‘‘Placebos and
Blinding in Randomized Controlled
Cancer Clinical Trials for Drug and
Biological Products.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
VerDate Sep<11>2014
17:00 Aug 28, 2019
Jkt 247001
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of this guidance to the Division
of Drug Information, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002; or the Office of Communication,
Outreach, and Development, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
3128, Silver Spring, MD 20993–0002.
Send one self-addressed adhesive label
to assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the guidance document.
FOR FURTHER INFORMATION CONTACT: Julia
Beaver, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
240–402–0489; or Stephen Ripley,
Center for Biologics Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 7301, Silver Spring,
MD 20993–0002, 240–402–7911.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a guidance for industry entitled
‘‘Placebos and Blinding in Randomized
Controlled Cancer Clinical Trials for
Drug and Biological Products.’’ This
guidance provides recommendations to
industry about using placebos and
blinding in randomized controlled
clinical trials in development programs
for drug or biological products to treat
hematologic malignancies and oncologic
diseases regulated by CDER and CBER.
This guidance finalizes the draft
guidance entitled ‘‘Hematologic
Malignancy and Oncologic Disease:
Considerations for Use of Placebos and
Blinding in Randomized Controlled
Clinical Trials for Drug Product
Development’’ (August 24, 2018, 83 FR
42902). Changes made to the guidance
took into consideration comments
received on the draft guidance and
include the following: (1) Clarifying that
unblinding should be limited to only
the patient and the investigator, (2)
clarifying that the guidance does not
address statistical approaches to
consider when unblinding data, (3)
making minor wording changes
throughout the document for clarity,
and (4) simplifying the guidance title.
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
45497
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on ‘‘Placebos and
Blinding in Randomized Controlled
Cancer Clinical Trials for Drug and
Biological Products.’’ It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations. This
guidance is not subject to Executive
Order 12866.
II. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collection of information in
21 CFR part 312 (Investigational New
Drug Application) has been approved
under OMB control number 0910–0014.
The collections of information in 21
CFR parts 50 and 56 (Protection of
Human Subjects: Informed Consent;
Institutional Review Boards) have been
approved under OMB control number
0910–0755.
III. Electronic Access
Persons with access to the internet
may obtain the guidance at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
vaccines-blood-biologics/guidancecompliance-regulatory-informationbiologics, or https://
www.regulations.gov.
Dated: August 26, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–18715 Filed 8–28–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–2381]
Horizontal Approaches to Food
Standards of Identity Modernization;
Public Meeting; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
The Food and Drug
Administration (FDA or we) is
SUMMARY:
E:\FR\FM\29AUN1.SGM
29AUN1
45498
Federal Register / Vol. 84, No. 168 / Thursday, August 29, 2019 / Notices
announcing a public meeting entitled
‘‘Horizontal Approaches to Food
Standards of Identity Modernization.’’
The purpose of the public meeting is to
give interested persons an opportunity
to discuss FDA’s effort to modernize
food standards of identity (SOI) and
provide information about changes we
could make to existing SOI, particularly
changes that could be made across
categories of standardized foods (i.e.,
horizontal changes), to provide
flexibility for the development of
healthier foods. We are also interested
in discussing horizontal changes that
would better facilitate innovation. This
effort is part of the FDA’s
comprehensive, multiyear Nutrition
Innovation Strategy (NIS) designed to
improve healthy dietary behavior and
help reduce preventable death and
disease related to poor nutrition by,
among other things, providing
incentives for food manufacturers to
produce products that have more
healthful attributes.
DATES: The public meeting will be held
on September 27, 2019, from 8:30 a.m.
to 5 p.m. Submit either electronic or
written comments on this public
meeting notice and request for
comments by November 12, 2019. See
the SUPPLEMENTARY INFORMATION section
for registration date and information.
ADDRESSES: The public meeting will be
held at the Hilton Washington DC/
Rockville Hotel, 1750 Rockville Pike,
Rockville, MD 20852. For more
information on the hotel see https://
www3.hilton.com/en/hotels/maryland/
hilton-washington-dc-rockville-hoteland-executive-meeting-ctr-IADMRHF/
index.html.
You may submit comments as
follows. Please note that late, untimely
filed comments will not be considered.
Electronic comments must be submitted
on or before November 12, 2019. The
https://www.regulations.gov electronic
filing system will accept comments
until 11:59 p.m. Eastern Time at the end
of November 12, 2019. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
khammond on DSKBBV9HB2PROD with NOTICES
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
VerDate Sep<11>2014
17:00 Aug 28, 2019
Jkt 247001
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–N–2381 for ‘‘Horizontal
Approaches to Food Standards of
Identity Modernization.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ We
will review this copy, including the
claimed confidential information, in our
consideration of comments. The second
copy, which will have the claimed
confidential information redacted/
blacked out, will be available for public
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
For questions about registering for the
meeting or to register by phone: Mark
Gifford, SIDEM, 1775 Eye St. NW, Suite
1150, Washington, DC 20006, telephone:
240–393–4496, Fax: 202–495–2901,
email: EventSupport@sidemgroup.com.
For general questions about the
meeting or for special accommodations
due to a disability: Juanita Yates, Center
for Food Safety and Applied Nutrition
(HFS–009), Food and Drug
Administration, 5001 Campus Dr.,
College Park, MD 20740, 240–402–1731,
email: Juanita.yates@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
A. Introduction
On January 11, 2018, FDA released its
2018 Strategic Policy Roadmap (https://
www.fda.gov/AboutFDA/Reports
ManualsForms/Reports/
ucm591993.htm), which focuses, in
part, on efforts to empower consumers
to make better and more informed
decisions about their diets and health,
foster the development of healthier food
options, and expand the opportunities
to use nutrition to reduce morbidity and
mortality due to chronic disease. The
roadmap highlights FDA’s commitment
to finding approaches to advance
policies that better achieve these goals.
On March 29, 2018, the Commissioner
of Food and Drugs announced a
comprehensive, multiyear FDA
Nutrition Innovation Strategy
E:\FR\FM\29AUN1.SGM
29AUN1
khammond on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 84, No. 168 / Thursday, August 29, 2019 / Notices
(hereinafter the ‘‘NIS’’) (to access the
speech, visit https://www.fda.gov/
NewsEvents/Speeches/ucm603057.htm).
The NIS focuses, among other things, on
providing incentives for food
manufacturers to produce products that
have more healthful attributes. Under
the NIS, FDA is seeking to modernize
food SOI in a manner that will achieve
three primary goals: (1) Protect
consumers against economic
adulteration; (2) maintain the basic
nature, essential characteristics, and
nutritional integrity of food; and (3)
promote industry innovation and
provide flexibility to encourage
manufacturers to produce more
healthful foods. To inform this effort,
we seek information from interested
stakeholders to learn what changes have
occurred in food production and
manufacturing that impact industry’s
ability to comply with current SOI
regulations and what we should be
aware of when reviewing and exploring
how to modernize our SOI regulations.
We are also interested in learning
whether we can achieve our SOI
modernization goals in ways that
produce cost savings.
Many foods have definitions and SOI
established by law. FDA began
establishing SOI to promote honesty and
fair dealing in the interest of consumers
shortly after the Federal Food, Drug, and
Cosmetic Act (FD&C Act) was enacted
in 1938. Since then, we have established
more than 280 SOI for a wide variety of
food products. SOI typically set forth
permitted ingredients, both mandatory
and optional, and sometimes specify the
amount or proportion of each
ingredient. Many SOI also designate the
method of production. A food is
misbranded if it purports to be or is
represented as a food for which a SOI
has been established but fails to
conform to the standard. See 21 U.S.C.
343(g). Because we issued many SOI
decades ago, various stakeholders have
expressed concerns that many SOI are
out of date and may impede innovation,
including the ability to produce
healthier foods.
SOI protect consumers against
economic adulteration and reflect
consumers’ expectations about food.
They may also describe the basic nature
and essential characteristics, including
nutritional characteristics, of the food
(see FDA’s May 20, 2005, proposed rule
entitled, ‘‘Food Standards; General
Principles and Food Standards
Modernization’’ (70 FR 29214) for a
discussion of the ‘‘basic nature’’ and
‘‘essential characteristics’’ of food). As
consumers continue to seek more
nutritious and healthful food options,
we seek to ensure that SOI meet these
VerDate Sep<11>2014
17:00 Aug 28, 2019
Jkt 247001
expectations. Modernizing SOI can give
manufacturers the flexibility to improve
the nutrition and healthfulness of
standardized foods, promote honesty
and fair dealing in the interest of
consumers, and help achieve the goals
of the NIS.
On July 26, 2018, FDA held a public
meeting to discuss the NIS (including
SOI modernization) and give interested
parties an opportunity to provide input.
During the public meeting, many
participants expressed general support
for FDA exploring modernization
options that could promote changes
across all, or broad categories of, SOI to
facilitate innovation and flexibility to
reformulate products to produce more
nutritious foods. Several participants
highlighted that rapid advances in
technology and science necessitated
revisions to certain SOI. The
participants, however, also stated that
updating individual standards (some
stakeholders have referred to this as a
‘‘vertical’’ approach) would be timeconsuming and may not be feasible
given FDA’s limited resources. They
proposed that a horizontal approach
that permits additional flexibility across
all or broad categories of standardized
foods could help resolve this issue by
allowing FDA to efficiently make
comprehensive changes that could
impact many standardized foods. For
example, several participants cited
FDA’s regulation entitled,
‘‘Requirements for foods named by use
of a nutrient content claim and a
standardized term’’ (21 CFR 130.10) as
a potential model. This regulation
provides for modified versions of
certain standardized foods that bear
descriptive names that are meaningful
to consumers (e.g., ‘‘fat free’’ and ‘‘low
calorie’’). Some participants also said
we should consider consumer demand
for healthful and nutritious foods as we
explore how to modernize in ways that
will allow food manufacturers to
produce more nutritious food options.
The NIS public meeting docket closed
on October 11, 2018, and resulted in
more than 5,000 comments. We have
reviewed the comments and are using
information provided to inform our
strategy moving forward.
There has been broad interest from
stakeholders regarding horizontal
approaches to SOI modernization. Some
offered concrete proposals about the
design and content of a regulation that
creates a horizontal standard to advance
SOI modernization. For example, in
October 2006, the Grocery
Manufacturers Association (GMA)
submitted a Citizen Petition asking FDA
to amend 21 CFR part 130 to modernize
food standards (see Docket ID: FDA–
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
45499
2007–P–0463–0367). The Citizen
Petition identified six categories of
variations from food standards that
GMA believed should be permitted to
provide flexibility. Several comments
submitted to the NIS docket cited
variations outlined in the GMA Citizen
Petition as examples of horizontal
standard options we should consider as
part of SOI modernization.
To maximize our limited resources,
we must consider efficient
modernization approaches that will
have the greatest potential impacts. As
such, we are interested in learning more
about horizontal approaches to SOI
modernization that will encourage
production of healthier foods and/or
facilitate innovation, specifically
allowing for use of new technologies
and new or novel ingredients. We
believe this focus supports the NIS goals
of reducing the burden of chronic
disease through improved nutrition.
Furthermore, this will allow FDA to
provide manufacturers with additional
flexibility without adversely impacting
the basic nature and essential
characteristics of standardized foods.
FDA is issuing this request for
comment and will hold a public
meeting on September 27, 2019, to
gather data and information from
stakeholders regarding horizontal
approaches to SOI modernization.
B. Legal Authority
Our authority to establish food
standards is set forth in section 401 of
the FD&C Act (21 U.S.C. 341). Section
401 of the FD&C Act authorizes us to
issue regulations fixing and establishing
for any food, under its common or usual
name so far as practicable, a reasonable
definition and standard of identity, a
reasonable standard of quality, or
reasonable standards of fill of container
when such action promotes honesty and
fair dealing in the interest of consumers.
The standards of identity, quality, and
fill of container for foods regulated by
FDA are codified in 21 CFR parts 130
to 169. FDA food standards are
established under the common or usual
name of a food.
II. Topics for Discussion at the Public
Meeting
The public meeting will explore
horizontal approaches to SOI
modernization that will support the
goals of the NIS. We are interested in
learning more about horizontal changes
that would improve the nutrition or
healthfulness of standardized foods
and/or provide for flexibility and
innovation in their production. We are
considering all horizontal approaches
that will ensure the basic nature and
E:\FR\FM\29AUN1.SGM
29AUN1
khammond on DSKBBV9HB2PROD with NOTICES
45500
Federal Register / Vol. 84, No. 168 / Thursday, August 29, 2019 / Notices
essential characteristics of food are
maintained. We also invite comment on
how these changes could be efficiently
accomplished. For example, we would
like to know whether horizontal SOI
might be a means for implementing the
changes and how such standards could
be structured.
The public meeting will begin with a
plenary session, followed by breakout
sessions that will discuss key topics
relating to horizontal approaches to SOI
modernization. Approximately 2 weeks
before the meeting, we will post the
public meeting agenda and additional
background materials on the internet at:
https://www.fda.gov/food/news-eventscfsan/workshops-meetings-webinarsfood-and-dietary-supplements. In
addition to the opportunity to comment
at the public meeting, there will be an
opportunity for interested stakeholders
to submit written comments following
the meeting (see DATES).
The first breakout session will explore
nutrition topics. We are interested in
learning what changes to existing SOI
would encourage production of more
nutritious foods. We are interested in
hearing stakeholder perspectives
regarding the role of nutrition in SOI
modernization and how a horizontal
approach to modernization could
encourage production of more nutritious
foods. We want to learn if current SOI
pose barriers to production of more
nutritious foods and, if so, understand
how horizontal changes to standardized
foods could help overcome these
barriers. We also invite comments
regarding how we could design a
horizontal standard to provide
manufacturers of standardized foods
with the flexibility to reflect future
advances in science and technology as
they relate to improved nutrition.
The second breakout session will
discuss issues related to innovation and
what horizontal approaches to
modernization could better
accommodate advances in science and
technology. We are interested in
learning how horizontal changes could
provide the flexibility necessary to
accommodate future industry
innovation while ensuring standardized
foods continue to meet consumer
expectations and maintain the basic
nature and essential characteristics of
food. We are particularly interested in
learning about horizontal changes to
manufacturing processes and permitted
ingredients that could promote
innovation. We request that comments
VerDate Sep<11>2014
17:00 Aug 28, 2019
Jkt 247001
indicate the foods to which a proposed
horizontal change would apply, the
current requirement(s) in the SOI to
which the change would apply, and the
specific change requested (e.g.,
additional manufacturing processes
permitted or ingredients permitted).
The third breakout session will
discuss issues related to consumer
expectations and standardized foods.
We are interested in learning what
flexibility we can provide in a
horizontal approach to modernization,
while ensuring standardized foods
continue to meet consumer
expectations. We want to learn about
consumers’ shifting expectations and
how horizontal changes could allow
innovation and product reformulation to
meet such demands. For example,
comments to the NIS public meeting
docket highlighted that consumers now
demand healthier foods and products
that meet specific dietary needs (e.g.,
‘‘gluten free’’ products). As SOI are
issued to ‘‘promote honesty and fair
dealing in the interest of consumers,’’
we believe the consumer perspective is
critical to understanding what flexibility
we should consider when exploring
horizontal changes to current SOI and
invite comments on what, if any,
limitations are appropriate to ensure
standardized foods continue to meet
consumer expectations.
We will consider all comments made
at this public meeting or received
through the docket (see ADDRESSES) as
we consider how horizontal changes
could support our SOI modernization
goals. Information concerning the FDA’s
NIS and more information on our work
to modernize SOI can be found at
https://www.fda.gov/food/food-labelingnutrition/fda-nutrition-innovationstrategy.
III. Participating in the Public Meeting
Registration: To register for the public
meeting, please visit the following
website: https://www.fda.gov/food/
news-events-cfsan/workshops-meetingswebinars-food-and-dietary-supplements.
Please provide complete contact
information for each attendee, including
name, title, affiliation, address, email,
and telephone.
Registration is free and based on
space availability. Persons interested in
attending this public meeting must
register by 11:59 p.m. on September 20,
2019. Early registration is recommended
because seating is limited; therefore,
FDA may limit the number of
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
participants from each organization.
Registrants will receive confirmation
when they have been accepted.
If you need special accommodations
due to a disability, please contact
Juanita Yates (see FOR FURTHER
INFORMATION CONTACT) no later than
September 12, 2019.
Requests for Oral Presentations:
During online registration you may
indicate if you wish to present during a
public comment session or participate
in a specific session, and which topic(s)
you wish to address. We will do our
best to accommodate requests to make
public comments. We urge individuals
and organizations with common
interests to consolidate or coordinate
their presentations, and request time for
a joint presentation, or submit requests
for designated representatives to
participate in the focused sessions. All
requests to make oral presentations
must be received by September 12,
2019. We will determine the amount of
time allotted to each presenter and the
approximate time each oral presentation
is to begin, and will select and notify
participants. Speakers will be limited to
making oral remarks; there will not be
an opportunity to display materials such
as slide shows, videos, or other media
during the meeting. No commercial or
promotional material will be permitted
to be presented or distributed at the
public meeting.
Persons attending FDA’s public
meetings are advised that FDA is not
responsible for providing access to
electrical outlets.
Streaming Webcast of the public
meeting: This public meeting will also
be webcast. Webcast participants are
asked to preregister at https://
www.fda.gov/food/news-events-cfsan/
workshops-meetings-webinars-food-anddietary-supplements.
Transcripts: Please be advised that as
soon as a transcript of the public
meeting is available, it will be accessible
at https://www.regulations.gov. It may
be viewed at the Dockets Management
Staff (see ADDRESSES). A link to the
transcript will also be available on the
internet at https://www.fda.gov/food/
news-events-cfsan/workshops-meetingswebinars-food-and-dietary-supplements.
Dated: August 23, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–18713 Filed 8–28–19; 8:45 am]
BILLING CODE 4164–01–P
E:\FR\FM\29AUN1.SGM
29AUN1
Agencies
[Federal Register Volume 84, Number 168 (Thursday, August 29, 2019)]
[Notices]
[Pages 45497-45500]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18713]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-2381]
Horizontal Approaches to Food Standards of Identity
Modernization; Public Meeting; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is
[[Page 45498]]
announcing a public meeting entitled ``Horizontal Approaches to Food
Standards of Identity Modernization.'' The purpose of the public
meeting is to give interested persons an opportunity to discuss FDA's
effort to modernize food standards of identity (SOI) and provide
information about changes we could make to existing SOI, particularly
changes that could be made across categories of standardized foods
(i.e., horizontal changes), to provide flexibility for the development
of healthier foods. We are also interested in discussing horizontal
changes that would better facilitate innovation. This effort is part of
the FDA's comprehensive, multiyear Nutrition Innovation Strategy (NIS)
designed to improve healthy dietary behavior and help reduce
preventable death and disease related to poor nutrition by, among other
things, providing incentives for food manufacturers to produce products
that have more healthful attributes.
DATES: The public meeting will be held on September 27, 2019, from 8:30
a.m. to 5 p.m. Submit either electronic or written comments on this
public meeting notice and request for comments by November 12, 2019.
See the SUPPLEMENTARY INFORMATION section for registration date and
information.
ADDRESSES: The public meeting will be held at the Hilton Washington DC/
Rockville Hotel, 1750 Rockville Pike, Rockville, MD 20852. For more
information on the hotel see https://www3.hilton.com/en/hotels/maryland/hilton-washington-dc-rockville-hotel-and-executive-meeting-ctr-IADMRHF/.
You may submit comments as follows. Please note that late, untimely
filed comments will not be considered. Electronic comments must be
submitted on or before November 12, 2019. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of November 12, 2019. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are postmarked or the delivery
service acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2018-N-2381 for ``Horizontal Approaches to Food Standards of
Identity Modernization.'' Received comments, those filed in a timely
manner (see ADDRESSES), will be placed in the docket and, except for
those submitted as ``Confidential Submissions,'' publicly viewable at
https://www.regulations.gov or at the Dockets Management Staff between
9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' We will review
this copy, including the claimed confidential information, in our
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information to be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify this information as ``confidential.''
Any information marked as ``confidential'' will not be disclosed except
in accordance with 21 CFR 10.20 and other applicable disclosure law.
For more information about FDA's posting of comments to public dockets,
see 80 FR 56469, September 18, 2015, or access the information at:
https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
For questions about registering for the meeting or to register by
phone: Mark Gifford, SIDEM, 1775 Eye St. NW, Suite 1150, Washington, DC
20006, telephone: 240-393-4496, Fax: 202-495-2901, email:
[email protected].
For general questions about the meeting or for special
accommodations due to a disability: Juanita Yates, Center for Food
Safety and Applied Nutrition (HFS-009), Food and Drug Administration,
5001 Campus Dr., College Park, MD 20740, 240-402-1731, email:
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
A. Introduction
On January 11, 2018, FDA released its 2018 Strategic Policy Roadmap
(https://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm591993.htm), which focuses, in part, on efforts to empower consumers
to make better and more informed decisions about their diets and
health, foster the development of healthier food options, and expand
the opportunities to use nutrition to reduce morbidity and mortality
due to chronic disease. The roadmap highlights FDA's commitment to
finding approaches to advance policies that better achieve these goals.
On March 29, 2018, the Commissioner of Food and Drugs announced a
comprehensive, multiyear FDA Nutrition Innovation Strategy
[[Page 45499]]
(hereinafter the ``NIS'') (to access the speech, visit https://www.fda.gov/NewsEvents/Speeches/ucm603057.htm). The NIS focuses, among
other things, on providing incentives for food manufacturers to produce
products that have more healthful attributes. Under the NIS, FDA is
seeking to modernize food SOI in a manner that will achieve three
primary goals: (1) Protect consumers against economic adulteration; (2)
maintain the basic nature, essential characteristics, and nutritional
integrity of food; and (3) promote industry innovation and provide
flexibility to encourage manufacturers to produce more healthful foods.
To inform this effort, we seek information from interested stakeholders
to learn what changes have occurred in food production and
manufacturing that impact industry's ability to comply with current SOI
regulations and what we should be aware of when reviewing and exploring
how to modernize our SOI regulations. We are also interested in
learning whether we can achieve our SOI modernization goals in ways
that produce cost savings.
Many foods have definitions and SOI established by law. FDA began
establishing SOI to promote honesty and fair dealing in the interest of
consumers shortly after the Federal Food, Drug, and Cosmetic Act (FD&C
Act) was enacted in 1938. Since then, we have established more than 280
SOI for a wide variety of food products. SOI typically set forth
permitted ingredients, both mandatory and optional, and sometimes
specify the amount or proportion of each ingredient. Many SOI also
designate the method of production. A food is misbranded if it purports
to be or is represented as a food for which a SOI has been established
but fails to conform to the standard. See 21 U.S.C. 343(g). Because we
issued many SOI decades ago, various stakeholders have expressed
concerns that many SOI are out of date and may impede innovation,
including the ability to produce healthier foods.
SOI protect consumers against economic adulteration and reflect
consumers' expectations about food. They may also describe the basic
nature and essential characteristics, including nutritional
characteristics, of the food (see FDA's May 20, 2005, proposed rule
entitled, ``Food Standards; General Principles and Food Standards
Modernization'' (70 FR 29214) for a discussion of the ``basic nature''
and ``essential characteristics'' of food). As consumers continue to
seek more nutritious and healthful food options, we seek to ensure that
SOI meet these expectations. Modernizing SOI can give manufacturers the
flexibility to improve the nutrition and healthfulness of standardized
foods, promote honesty and fair dealing in the interest of consumers,
and help achieve the goals of the NIS.
On July 26, 2018, FDA held a public meeting to discuss the NIS
(including SOI modernization) and give interested parties an
opportunity to provide input. During the public meeting, many
participants expressed general support for FDA exploring modernization
options that could promote changes across all, or broad categories of,
SOI to facilitate innovation and flexibility to reformulate products to
produce more nutritious foods. Several participants highlighted that
rapid advances in technology and science necessitated revisions to
certain SOI. The participants, however, also stated that updating
individual standards (some stakeholders have referred to this as a
``vertical'' approach) would be time-consuming and may not be feasible
given FDA's limited resources. They proposed that a horizontal approach
that permits additional flexibility across all or broad categories of
standardized foods could help resolve this issue by allowing FDA to
efficiently make comprehensive changes that could impact many
standardized foods. For example, several participants cited FDA's
regulation entitled, ``Requirements for foods named by use of a
nutrient content claim and a standardized term'' (21 CFR 130.10) as a
potential model. This regulation provides for modified versions of
certain standardized foods that bear descriptive names that are
meaningful to consumers (e.g., ``fat free'' and ``low calorie''). Some
participants also said we should consider consumer demand for healthful
and nutritious foods as we explore how to modernize in ways that will
allow food manufacturers to produce more nutritious food options. The
NIS public meeting docket closed on October 11, 2018, and resulted in
more than 5,000 comments. We have reviewed the comments and are using
information provided to inform our strategy moving forward.
There has been broad interest from stakeholders regarding
horizontal approaches to SOI modernization. Some offered concrete
proposals about the design and content of a regulation that creates a
horizontal standard to advance SOI modernization. For example, in
October 2006, the Grocery Manufacturers Association (GMA) submitted a
Citizen Petition asking FDA to amend 21 CFR part 130 to modernize food
standards (see Docket ID: FDA-2007-P-0463-0367). The Citizen Petition
identified six categories of variations from food standards that GMA
believed should be permitted to provide flexibility. Several comments
submitted to the NIS docket cited variations outlined in the GMA
Citizen Petition as examples of horizontal standard options we should
consider as part of SOI modernization.
To maximize our limited resources, we must consider efficient
modernization approaches that will have the greatest potential impacts.
As such, we are interested in learning more about horizontal approaches
to SOI modernization that will encourage production of healthier foods
and/or facilitate innovation, specifically allowing for use of new
technologies and new or novel ingredients. We believe this focus
supports the NIS goals of reducing the burden of chronic disease
through improved nutrition. Furthermore, this will allow FDA to provide
manufacturers with additional flexibility without adversely impacting
the basic nature and essential characteristics of standardized foods.
FDA is issuing this request for comment and will hold a public
meeting on September 27, 2019, to gather data and information from
stakeholders regarding horizontal approaches to SOI modernization.
B. Legal Authority
Our authority to establish food standards is set forth in section
401 of the FD&C Act (21 U.S.C. 341). Section 401 of the FD&C Act
authorizes us to issue regulations fixing and establishing for any
food, under its common or usual name so far as practicable, a
reasonable definition and standard of identity, a reasonable standard
of quality, or reasonable standards of fill of container when such
action promotes honesty and fair dealing in the interest of consumers.
The standards of identity, quality, and fill of container for foods
regulated by FDA are codified in 21 CFR parts 130 to 169. FDA food
standards are established under the common or usual name of a food.
II. Topics for Discussion at the Public Meeting
The public meeting will explore horizontal approaches to SOI
modernization that will support the goals of the NIS. We are interested
in learning more about horizontal changes that would improve the
nutrition or healthfulness of standardized foods and/or provide for
flexibility and innovation in their production. We are considering all
horizontal approaches that will ensure the basic nature and
[[Page 45500]]
essential characteristics of food are maintained. We also invite
comment on how these changes could be efficiently accomplished. For
example, we would like to know whether horizontal SOI might be a means
for implementing the changes and how such standards could be
structured.
The public meeting will begin with a plenary session, followed by
breakout sessions that will discuss key topics relating to horizontal
approaches to SOI modernization. Approximately 2 weeks before the
meeting, we will post the public meeting agenda and additional
background materials on the internet at: https://www.fda.gov/food/news-events-cfsan/workshops-meetings-webinars-food-and-dietary-supplements.
In addition to the opportunity to comment at the public meeting, there
will be an opportunity for interested stakeholders to submit written
comments following the meeting (see DATES).
The first breakout session will explore nutrition topics. We are
interested in learning what changes to existing SOI would encourage
production of more nutritious foods. We are interested in hearing
stakeholder perspectives regarding the role of nutrition in SOI
modernization and how a horizontal approach to modernization could
encourage production of more nutritious foods. We want to learn if
current SOI pose barriers to production of more nutritious foods and,
if so, understand how horizontal changes to standardized foods could
help overcome these barriers. We also invite comments regarding how we
could design a horizontal standard to provide manufacturers of
standardized foods with the flexibility to reflect future advances in
science and technology as they relate to improved nutrition.
The second breakout session will discuss issues related to
innovation and what horizontal approaches to modernization could better
accommodate advances in science and technology. We are interested in
learning how horizontal changes could provide the flexibility necessary
to accommodate future industry innovation while ensuring standardized
foods continue to meet consumer expectations and maintain the basic
nature and essential characteristics of food. We are particularly
interested in learning about horizontal changes to manufacturing
processes and permitted ingredients that could promote innovation. We
request that comments indicate the foods to which a proposed horizontal
change would apply, the current requirement(s) in the SOI to which the
change would apply, and the specific change requested (e.g., additional
manufacturing processes permitted or ingredients permitted).
The third breakout session will discuss issues related to consumer
expectations and standardized foods. We are interested in learning what
flexibility we can provide in a horizontal approach to modernization,
while ensuring standardized foods continue to meet consumer
expectations. We want to learn about consumers' shifting expectations
and how horizontal changes could allow innovation and product
reformulation to meet such demands. For example, comments to the NIS
public meeting docket highlighted that consumers now demand healthier
foods and products that meet specific dietary needs (e.g., ``gluten
free'' products). As SOI are issued to ``promote honesty and fair
dealing in the interest of consumers,'' we believe the consumer
perspective is critical to understanding what flexibility we should
consider when exploring horizontal changes to current SOI and invite
comments on what, if any, limitations are appropriate to ensure
standardized foods continue to meet consumer expectations.
We will consider all comments made at this public meeting or
received through the docket (see ADDRESSES) as we consider how
horizontal changes could support our SOI modernization goals.
Information concerning the FDA's NIS and more information on our work
to modernize SOI can be found at https://www.fda.gov/food/food-labeling-nutrition/fda-nutrition-innovation-strategy.
III. Participating in the Public Meeting
Registration: To register for the public meeting, please visit the
following website: https://www.fda.gov/food/news-events-cfsan/workshops-meetings-webinars-food-and-dietary-supplements. Please
provide complete contact information for each attendee, including name,
title, affiliation, address, email, and telephone.
Registration is free and based on space availability. Persons
interested in attending this public meeting must register by 11:59 p.m.
on September 20, 2019. Early registration is recommended because
seating is limited; therefore, FDA may limit the number of participants
from each organization. Registrants will receive confirmation when they
have been accepted.
If you need special accommodations due to a disability, please
contact Juanita Yates (see FOR FURTHER INFORMATION CONTACT) no later
than September 12, 2019.
Requests for Oral Presentations: During online registration you may
indicate if you wish to present during a public comment session or
participate in a specific session, and which topic(s) you wish to
address. We will do our best to accommodate requests to make public
comments. We urge individuals and organizations with common interests
to consolidate or coordinate their presentations, and request time for
a joint presentation, or submit requests for designated representatives
to participate in the focused sessions. All requests to make oral
presentations must be received by September 12, 2019. We will determine
the amount of time allotted to each presenter and the approximate time
each oral presentation is to begin, and will select and notify
participants. Speakers will be limited to making oral remarks; there
will not be an opportunity to display materials such as slide shows,
videos, or other media during the meeting. No commercial or promotional
material will be permitted to be presented or distributed at the public
meeting.
Persons attending FDA's public meetings are advised that FDA is not
responsible for providing access to electrical outlets.
Streaming Webcast of the public meeting: This public meeting will
also be webcast. Webcast participants are asked to preregister at
https://www.fda.gov/food/news-events-cfsan/workshops-meetings-webinars-food-and-dietary-supplements.
Transcripts: Please be advised that as soon as a transcript of the
public meeting is available, it will be accessible at https://www.regulations.gov. It may be viewed at the Dockets Management Staff
(see ADDRESSES). A link to the transcript will also be available on the
internet at https://www.fda.gov/food/news-events-cfsan/workshops-meetings-webinars-food-and-dietary-supplements.
Dated: August 23, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-18713 Filed 8-28-19; 8:45 am]
BILLING CODE 4164-01-P